Riccardo Dalla-Favera

USPTO Granted Patents = 14 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 1.5

ph-index = 5

Forward Citations = 71(Granted Patents)

Company Filing History:

Sloan-kettering Institute for Cancer Research

4. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2013

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8586726 - Tissue-specific MicroRNAs and compositions and uses thereof (2013-11-19),

2. 8299220 - Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma (2012-10-30),

3. 7863424 - Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma (2011-01-04),

4. 7105149 - Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma (2006-09-12),

5. 6958386 - MUM-1 protein expressed by multiple myeloma-related gene (2005-10-25),

6. 6783945 - Cloning and uses of the genetic locus bcl-6 (2004-08-31),

7. 6309860 - Cloning and uses of BCL-8 (2001-10-30),

8. 6268138 - Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs (2001-07-31),

9. 6245562 - Identification of genes altered in multiple myeloma (2001-06-12),

10. 6174997 - Cloning and uses of the genetic locus BCL-6 (2001-01-16),

11. 5888820 - Retroviral vector capable of transducing the aldehyde dehydrogenase-1 (1999-03-30),

12. 5882858 - Cloning and uses of the genetic locus BCL-6 (1999-03-16),

13. 5641672 - Cloning and uses of the genetic locus bcl-6 (1997-06-24),

14. 5223417 - Method for transforming human B lymphocytes (1993-06-29),

Title: Riccardo Dalla-Favera: Innovator in Cancer Research

Introduction

Riccardo Dalla-Favera is a prominent inventor based in New York, NY, known for his significant contributions to cancer research. He holds a total of 14 patents, showcasing his innovative work in the field of molecular biology and oncology. His research has led to groundbreaking discoveries that have the potential to improve diagnosis and treatment for B cell malignancies.

Latest Patents

Dalla-Favera's latest patents include "Tissue-specific MicroRNAs and compositions and uses thereof," which provides isolated nucleic acid sequences of newly discovered micro RNAs found in normal and tumor-related human B cells. This invention utilizes an integrated bioinformatics method to identify these micro RNAs. Another notable patent is "Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma." This invention offers an isolated nucleic acid molecule encoding immunoglobulin receptor proteins, including IRTA1, IRTA2, IRTA3, IRTA4, and IRTA5. The patent also includes methods for detecting and diagnosing B cell malignancies, as well as treating subjects with B cell cancer.

Career Highlights

Dalla-Favera has had a distinguished career, primarily associated with Columbia University, where he has conducted extensive research in cancer biology. His work has been instrumental in advancing the understanding of the genetic factors involved in B cell malignancies.

Collaborations

Throughout his career, Dalla-Favera has collaborated with notable colleagues, including Raju S K Chaganti and Raju S Chaganti, contributing to various research projects and publications in the field of oncology.

Conclusion

Riccardo Dalla-Favera's innovative work and numerous patents have made a significant impact on cancer research, particularly in understanding and treating B cell malignancies. His contributions continue to influence the field and pave the way for future advancements in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.